Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2018 / N 1

Возможности периндоприла в лечении артериальной гипертонии в различных клинических ситуациях
О.Д. Остроумова, Е.А. Смолярчук, А.А. Зыкова, Г.Ф. Пиксина

Список литературы
1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 Jul;31(7):1281-357.
2. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010;3:5-26.
3. Руководство по артериальной гипертонии. Под ред. Чазова Е.И., Чазовой И.Е. М.: Медиа Медика; 2005. 784 с.
4. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 Jan;295(2):180-9.
5. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 2000 Jan;342(3):145-53.
6. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo-controlled, multicentre trial (EUROPA study). Lancet 2003 Sep; 362(9386):782-8.
7. Pitt B, O’Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS; QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. American Journal of Cardiology 2001 May;87(9):1058-63.
8. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. The New England Journal of Medicine 2004 Nov;351(20):2058-68.
9. Всероссийское научное общество кардиологов. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2008;7(6, приложение 4):4-40.
10. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 Oct;27(19):2338-45.
11. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Annals of Internal Medicine 2010 Jan;152(2):78-84.
12. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журнал неврологии и психиатрии им. С.С. Корсакова 2007;107(8):1-11.
13. Wilterdink JI, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Archives of Neurology 1992 Aug;49(8):857-63.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-41.
15. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 Jan;42(1):227-76.
16. Чазова И.Е., Недогода С.В., Жернакова Ю.В., Сусеков А.В., Медведева И.В., Шестакова М.В. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестник 2014;IX(1):3-57.
17. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
18. Vrablík M, Freiberger T, Lánská V, Češka R on behalf of the Project Investigators. The ATRACTIV Project: improved cardiovascular prevention in the context of primary care in the Czech Republic. Vnitřní lékařství 2008;54(12):871-8.
19. Сахарный диабет: диагностика, лечение, профилактика. Под ред. Дедова И.И., Шестаковой М.В. М.: МИА; 2011: 98,103-8,124-52.
20. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Groop. Diabetes Care 1996 Jul;19(7):689-97.
21. Chair H, Sowers JR. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994 Feb;23(2):145-58.
22. Шестакова М.В. Сахарный диабет и артериальная гипертония. В кн.: Руководство по артериальной гипертонии. Под ред. Чазова Е.И., Чазовой И.Е. Москва: Медиа Медика; 2005:415-33.
23. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep;370(9590):829-40.
24. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. The New England Journal of Medicine 2014 Oct;371(15):1392-406.
25. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. European Heart Journal 1992 Sep;13(Suppl D):82-8.
26. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlöf B. Effects of once-daily angiotensin-convertion enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001 Sep;104(11):1248-54.
27. Dahlöf B, Gosse P, Guéret P, Dubourg O, de Simone G, Schmieder R, Karpov Y, García-Puig J, Matos L, De Leeuw PW, Degaute JP, Magometschnigg D; PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reduction blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension 2005 Nov;23(11):2063-70.
28. Parving HH. Initiation and progression of diabetic nephropathy. The New England Journal of Medicine 1996 Nov;335(22):1682-3.
29. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Current Opinion in Nephrology and Hypertension 1993 Nov;2(6):962-7.
30. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000 Apr;35(4):898-903.
31. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Archives of Internal Medicine 2004 Dec;164(22):2459-64.
32. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001 Jul;286(4):421-6.
33. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 Mar;19(3):617-24.
34. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension 1998 Sep;16(9):1325-33.
35. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. American Journal of Kidney Diseases 2004;43(Suppl 1):S16-S33.
36. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 Oct;106(14):1777-82.
37. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. Journal of the American Society of Nephrology 2009 Aug;20(8):1813-21.
38. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010 Jun;375(9731):2073-81.
39. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007 Apr;369(9568):1208-19.
40. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Annals of Internal Medicine 2008 Jan;148(1):30-48.
41. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. The New England Journal of Medicine 2011 Mar;364(10):907-17.
42. Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 2011 Feb;29(2):207-16.
43. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A, Thomas SM; Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of Low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003 May;41(5):1063-71.
44. Верткин А.Л., Чижова Е.В. Нефропротективный эффект комбинации периндоприла с индапамидом у пациентов с артериальной гипертензией и высоким сердечно-сосудистым риском. Амбулаторный прием 2017;3(1):29-34.
45. Драпкина О.М. Комбинированная терапия пациентов высокого риска в условиях реальной клинической практики. Результаты исследования СИНЕРГИЯ. Часть 1. Антигипертензивная ветвь. Рациональная фармакотерапия в кардиологии 2017;13(2):155-63.
References
1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 Jul;31(7):1281-357.
2. Chazova IE, Ratova LG, Boitsov SA, Nebieridze DV. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension 2010;3:5-26 (In Russian).
3. Guidelines for the management of arterial hypertension. Chazov EI, Chasova EI, editors. Moscow: Media Medica; 2005. 784 p. (In Russian).
4. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 Jan;295(2):180-9.
5. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 2000 Jan;342(3):145-53.
6. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo-controlled, multicentre trial (EUROPA study). Lancet 2003 Sep; 362(9386):782-8.
7. Pitt B, O’Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS; QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. American Journal of Cardiology 2001 May;87(9):1058-63.
8. Braunwald E1, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. The New England Journal of Medicine 2004 Nov;351(20):2058-68.
9. All-Russian Scientific Society of Cardiologists. Diagnosis and treatment of stable angina pectoris. Russian recommendations (second revision). Cardiovascular Therapy and Prevention 2008;7(6 Suppl 4):4-40 (In Russian).
10. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 Oct;27(19):2338-45.
11. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Annals of Internal Medicine 2010 Jan;152(2):78-84.
12. Gusev EL, Skvortsova VL, Stakhovskaya LV. Stroke in the Russian Federation: time for united concentrated activities. SS Korsakov Journal of Neurology and Psychiatry 2007;107(8):1-11 (In Russian).
13. Wilterdink JI, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Archives of Neurology 1992 Aug;49(8):857-63.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-41.
15. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 Jan;42(1):227-76.
16. Chazova IE, Nedogoda SV, Zhernakova YuV, Susekov AV, Medvedeva IV, Shestakova MV. Guidelines for management of patients with arterial hypertension and metabolic disorders. Cardiologicheskiy vestnic 2014;IX(1):3-57 (In Russian).
17. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
18. Vrablík M, Freiberger T, Lánská V, Češka R on behalf of the Project Investigators. The ATRACTIV Project: improved cardiovascular prevention in the context of primary care in the Czech Republic. Vnitřní lékařství 2008;54(12):871-8.
19. Diabetes mellitus type: diagnosis, treatment, prevention. Dedov II. Shestakova MV, editors. Moscow: MIA; 2011:98,103-8,124-52 (In Russian).
20. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Groop. Diabetes Care 1996 Jul;19(7):689-97.
21. Chair H, Sowers JR. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994 Feb;23(2):145-58.
22. Shestakova MV. Diabetes mellitus and arterial hypertension. In: Guidelines for the management of arterial hypertension. Chazov EI, Chasova EI, editors. Moscow: Media Medika; 2005:415-33 (In Russian).
23. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep;370(9590):829-40.
24. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. The New England Journal of Medicine 2014 Oct;371(15):1392-406.
25. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. European Heart Journal 1992 Sep;13(Suppl D):82-8.
26. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlöf B. Effects of once-daily angiotensin-convertion enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001 Sep;104(11):1248-54.
27. Dahlöf B, Gosse P, Guéret P, Dubourg O, de Simone G, Schmieder R, Karpov Y, García-Puig J, Matos L, De Leeuw PW, Degaute JP, Magometschnigg D; PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reduction blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension 2005 Nov;23(11):2063-70.
28. Parving HH. Initiation and progression of diabetic nephropathy. The New England Journal of Medicine 1996 Nov;335(22):1682-3.
29. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Current Opinion in Nephrology and Hypertension 1993 Nov;2(6):962-7.
30. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000 Apr;35(4):898-903.
31. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Archives of Internal Medicine 2004 Dec;164(22):2459-64.
32. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001 Jul;286(4):421-6.
33. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 Mar;19(3):617-24.
34. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension 1998 Sep;16(9):1325-33.
35. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. American Journal of Kidney Diseases 2004;43(Suppl 1):S16-S33.
36. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 Oct;106(14):1777-82.
37. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. Journal of the American Society of Nephrology 2009 Aug;20(8):1813-21.
38. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010 Jun;375(9731):2073-81.
39. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007 Apr;369(9568):1208-19.
40. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Annals of Internal Medicine 2008 Jan;148(1):30-48.
41. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. The New England Journal of Medicine 2011 Mar;364(10):907-17.
42. Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 2011 Feb;29(2):207-16.
43. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A, Thomas SM; Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of Low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003 May;41(5):1063-71.
44. Vertkin AL, Chizhova EV. Renal protection effect of the combination of perindopril with indapamide in patients with arterial hypertension and high cardiovascular risk. Ambulatorniy Priyem 2017;3(1):29-34 (In Russian).
45. Drapkina OM. Combination therapy of high-risk patients in real clinical practice. Results of SYNERGY Study. Part 1. Antihypertensive Branch. Rational Pharmacotherapy in Cardiology 2017;13(2):155-63 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]